Standard Cosentyx Dosage for Psoriatic Arthritis and Ankylosing Spondylitis
Cosentyx (secukinumab), approved for severe cases of plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), starts with a 300 mg subcutaneous dose at weeks 0, 1, 2, 3, and 4. Maintenance follows every 4 weeks from week 4. This applies to adults and children over 6 with plaque psoriasis weighing more than 90 kg.[1][2]
Dosage for Severe Plaque Psoriasis
For severe plaque psoriasis in adults, use the 300 mg loading dose (five weekly injections via prefilled syringe, autoinjector, or pen). Switch to 300 mg every 4 weeks. Patients under 90 kg or with milder severity may drop to 150 mg after loading. Children 6+ weighing 50-90 kg get 150 mg loading (300 mg total over 4 weeks), then 150 mg every 4 weeks.[1][3]
Adjustments for PsA and AS in Severe Cases
Severe PsA or AS follows the same 300 mg loading regimen, then 150-300 mg every 4 weeks based on response. No weight-based changes, but clinicians assess severity via disease activity scores like ASDAS for AS.[2][4]
How Long Until It Works in Severe Disease
Peak efficacy appears by week 12-16 in trials for severe psoriasis (PASI 90 response in 70-80% of patients). For PsA/AS, pain and function improve within 2-4 weeks, with full benefits by week 16.[1][5]
Common Side Effects in High-Dose Severe Cases
Infections (upper respiratory, 20-30%), diarrhea (10%), and injection-site reactions (5-10%) rise slightly at 300 mg. Monitor for IBD flares or tuberculosis reactivation in severe inflammatory cases.[1][2]
When to Adjust or Switch Dosage
Reduce to 150 mg if well-controlled; discontinue if no response by week 12-16. Avoid in active infections. No dose cap for severity, but combine with methotrexate in PsA if needed.[3][4]
Sources:
[1] Cosentyx Prescribing Information (Novartis, 2023) - cosentyx.com
[2] FDA Label for Secukinumab - accessdata.fda.gov
[3] American Academy of Dermatology Guidelines (2021)
[4] EULAR Recommendations for AS/PsA (2022)
[5] Phase 3 Trial Data (NEJM, 2014) - No patents listed on DrugPatentWatch.com for dosage specifics.